GSK saw the highest growth of 1.13% in patent filings in May and 1.32% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.79% and grants by 1.32%. GlobalData’s DataBook provides a comprehensive analysis of GSK‘s patent filings and grants. Buy the databook here.
GSK has been focused on protecting inventions in United States(US) with 50 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 26% filings and 22% grants. The United States(US), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and Japan(JP) patent Office are among the top ten patent offices where GSK is filings its patents. Among the top granted patent authorities, GSK has 22% of its grants in United States(US), 17% in Spain(ES) and 12% in Japan(JP).
Roche could be the strongest competitor for GSK
Patents related to rare diseases and nanomedicine lead GSK's portfolio
GSK has the highest number of patents in rare diseases followed by, nanomedicine and climate change. For rare diseases, nearly 36% of patents were filed and 38% of patents were granted in Q2 2024.
Human immunodeficiency virus (hiv) infections (aids) related patents lead GSK portfolio followed by fibrosis, and alzheimer's disease
GSK has highest number of patents in human immunodeficiency virus (hiv) infections (aids) followed by fibrosis, alzheimer's disease, chronic obstructive pulmonary disease (copd), and ovarian cancer. For human immunodeficiency virus (hiv) infections (aids), nearly 7% of patents were filed and 10% of patents were granted in Q2 2024.
For comprehensive analysis of GSK's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.